The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma

British Journal of Urology

Volumn 79, Issue 2, 1997, Pages 190-195

  Byrne, R L ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Apoptosis; bcl 2; p53; Prostate cancer; waf 1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BIOPSY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR GROWTH;

EID: 0031397368     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1997.03399.x     Document Type: Article

References (35)

1. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Concur Res 1990; 50: 3748-53
2. Diller L, Kassal J, Nelson CE et al. p53 functions as a cell cycle arrest control protein in osteosarcomas. Mol Cell Biol 1990; 10: 5772-81
3. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild type p53. Science 1990; 249: 912-5
4. Martinez J, Georgoff I, Martinez J, Levine AJ, Cellular localisation and cell cycle regulation by a temperature sensitive p53 protein. Genes Dev 1991; 5: 151-9
5. Michalovitz D, Halevy O, Oren M. Conditioned inhibition of transformation and of cell proliferation by a temperature sensitive mutant of p53. Cell 1990; 62: 671-80
6. Lowe SW, Schmitt EM, Smith SW, Osbourne BA, Jacks T. p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-9
7. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms results from mistakes in VDJ joining. Science 1985; 229: 1390-3
8. Cleary ML, Sklar J. Nucleotide sequence of a t(14:18) chromosome breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18 Proc Natl Acad Sci USA 1985: 82: 7439-43
9. Navone N, Troncoso P, Pisters LL et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85: 1657-99
10. Aprikian AG, Sarkis AS, Fair WR, Zhang Z-F, Fuks Z, Cordon-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994; 151: 1276-80
11. Colombel M, Olsson CA, Ng P-Y, Buttyan R. Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res 1992; 52: 4313-9
12. El-Diery WS, Tokino T, Velculescu VE et al. WAF-1, a potential mediator of p53 tumour suppression. Cell 1993; 75: 817-25
13. El-Diery WS, Harper JW, O'Connor PM et al. WAF1/CIP1 is induced in p21-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-74
14. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild type p53 in a human colon tumor-derived cell line. Proct Natl Acad Sci USA 1992; 89: 4495-9
15. Lowe SW, Schmitt EM, Smith SW, Osbourne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-9
16. Kastan MB, Onyerkwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 53: 6304-11
17. Lane DP. p53, guardian of the genome. Nature 1992; 358: 15-6
18. Fosså SD, Smith PH. Treatment of relapsed disease - what is the choice? In Peeling B ed, Questions and Uncertainties about Prostate Cancer. Oxford: Blackwell Science 1996: 270-82
19. Meyers RB, Oelschlager D, Srivastava S, Grizzle WE. Accumulation of the p53 protein occurs more frequently in metastatic than localized prostatic adenocarcinomas. Prostate 1994; 25: 243-8
20. Mellon K, Thompson S, Charlton RG et al p53, c-erbB2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 1992; 147: 496-9
21. Baas IO, Mulder J-W R, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172: 5-12
22. Reich NC, Oren M, Levine AJ. Two distinct mechanisms regulate the levels of a cellular tumor antigen. p53. Mol Cell Biol 1983; 3: 2143-50
23. Lane DP, Benchimol S. P53 oncogene or anti-oncogene? Genes Dev 1990; 4: 1-8
24. Wynford-Thomas D. Editorial. p53 in tumour pathology: can we trust immunocytochemistry? J Pathol 1992; 166: 329-30
25. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991; 51: 4716-20
26. Carter BS, Ewing CM. Waed WS et al. Allelic loss of chromosomes 16q and 10 q in human prostate cancer. Proc Natl Acad Sci USA 1990; 87: 8751-5
27. Hockenbury DM, Zutter M, Hichey W, Naham M, Korsemeyer SJ. Bcl-2 protein is topographically restricted in tissue characterized by apoptotic cell death. Nature 1991, 348: 334-6
28. McDonnell TJ, Tronocoso P, Brisbay SM et al. Expression of the protooncogene bcl-2 in prostate and its association with the emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-4
29. Apakama I, Robinson MC. Walker N et al. bcl-2 overexpression combined with p53 nuclear protein accumulation correlates with hormone refractory prostate cancer. Br J Cancer 1996: in press.
30. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL, Bcl-2 in normal human breast carcinoma, associated with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in-situ cancer. Br J Cancer 1994; 69: 135-9
31. Öfner D, Riehemann K, Maier H et al. Immmunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer 1995; 72: 981-5
32. WAF1/Cip1 in colorectal carcinoma. Br J Cancer 1996; 74: 165-71
33. Macleod KF, Sherry N, Hannon G et al. p53-dependent and independent expression of p21 during cell growth, differentiation and DNA damage. Genes Dev 1995; 9: 935-44
34. Steinman RA, Huffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME. Induction of p21 (WAF1/CIP1) during differentiation. Oncogene 1994; 9: 3389-96
35. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-84